Sprint Corporation (NYSE:S) announced hat it and certain of its subsidiaries have entered into a facility agreement of up to $1.3 billion with The Bank of Tokyo-Mitsubishi UFJ, Ltd., as administrative agent, based on the securitization of its wireless service accounts receivable. Other banks involved in the facility are The Bank of Nova Scotia, Mizuho Bank, LTD., and Sumitomo Mitsui Banking Corporation. The new facility is expected to provide supplemental liquidity for general corporate purposes. Sprint Corporation (NYSE:S) net profit margin is -7.80% and weekly performance is 2.27%. On last trading day company shares ended up $9.01. Analysts mean target price for the company is $7.28. Sprint Corporation (NYSE:S) distance from 50-day simple moving average (SMA50) is 2.88%.
AT&T Inc. (NYSE:T) recently announced the deployment of its 8000 th compressed natural gas (CNG) vehicle, consistent with its plan of deploying 15,000 alternative fuel vehicles by 2018. AT&T Inc. (NYSE:T) shares advanced 0.60% in last trading session and ended the day on $36.74. Gross Margin is 59.80% and its return on assets is 6.60%. AT&T Inc. (NYSE:T) quarterly performance is 12.29%.
Shire PLC (ADR) (NASDAQ:SHPG) has earned an average recommendation of “Buy” from the twenty-one brokerages that are currently covering the stock, Analyst RN reports. Five research analysts have rated the stock with a hold recommendation, twelve have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $173.85.Shire PLC (ADR) (NASDAQ:SHPG) shares moved down -0.29% in last trading session and was closed at $166.00, while trading in range of $163.09 – $166.16.
A Chinese probe into GlaxoSmithKline Plc. (ADR) (NYSE:GSK) ’s local sales practices should send a warning to other foreign companies doing business in the country that “ethics matter,” the official news agency Xinhua said in an editorial. “GSK’s practices in China tainted both the company’s reputation and its credibility worldwide,” the editorial said. It appeared two days after Chinese police handed a case to prosecutors alleging that the former head of Glaxo’s China unit, British national Mark Reilly, ordered sales teams to bribe hospitals and doctors to boost drug sales. GlaxoSmithKline plc (ADR) (NYSE:GSK) ended the last trading day at $55.43. Company weekly volatility is calculated as 0.97% and price to cash ratio as 22.21. GlaxoSmithKline plc (ADR) (NYSE:GSK) showed a positive weekly performance of 1.97%.
ASTELLAS PHARMA INC (OTCMKTS:ALPMY) and Medivation Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Application (sNDA) to extend the indication for XTANDI® (enzalutamide) capsules for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) who have not received chemotherapy. This sNDA application was granted Priority Review designation with a stated FDA Prescription Drug User Fee Act (PDUFA) review date of September 18, 2014. XTANDI is currently approved for the treatment of patients with mCRPC who have previously received docetaxel chemotherapy. ASTELLAS PHARMA INC (OTCMKTS:ALPMY) on last trading day company shares ended up $11.74 .